Activity of Amphotericin B and Anidulafungin Combined with Rifampicin, Clarithromycin, Ethylenediaminetetraacetic Acid, N-Acetylcysteine, and Farnesol against Candida tropicalis Biofilms

We evaluated the activity of (1) amphotericin-B (AMB), combined with rifampicin (RIF), clarithromycin (CLA), N-acetylcysteine (NAC), ethylenediaminetetraacetic acid (EDTA), and farnesol (FAR) (1000, 1000, 1000, 4000, and 30,000 mg/L, and 300 µM, respectively), against Candida tropicalis biofilms formed on polytetrafluoroethylene (PTFE) and (2) anidulafungin (ANF) combined with the same compounds at 8, 10, 5, 40, and 30 mg/L, and 30 µM, respectively, against biofilms formed on titanium. Biofilm growth kinetics were performed in a CDC Biofilm Reactor (CBR). PTFE or titanium disks were removed from the CBR at 24, 48, 72, and 96 h to determine the Log10CFU/cm2. Killing kinetics were performed by adding the drugs to 24-h-mature biofilms (time 0). Disks were removed after 24, 48, and 72 h of drug exposure to determine Log10CFU/cm2. Viable cells in biofilms were 4.73 and 4.29 Log10CFU/cm2 on PTFE and titanium, respectively. Maximum Log10 decreases in CFU/cm2 depend on the combination and were: 3.53 (AMB + EDTA), 2.65 (AMB + RIF), 3.07 (AMB + NAC), 2.52 (AMB + CLA), 1.49 (AMB + FAR), 2.26 (ANF + EDTA), 2.45 (ANF + RIF), 2.47 (ANF + NAC), 1.52 (ANF + CLA), and 0.44 (ANF + FAR). In conclusion, EDTA, NAC, RIF, and CLA improve the activity of AMB and ANF against biofilms developed on both surfaces, which could be an effective strategy against C. tropicalis biofilm-related infections.

[1]  Elizabeth L. Alexander,et al.  In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms. , 2015, The Journal of antimicrobial chemotherapy.

[2]  G. Jürgens,et al.  Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[3]  J. Paiva,et al.  Pharmacokinetics of Anidulafungin in Critically Ill Patients with Candidemia/Invasive Candidiasis , 2013, Antimicrobial Agents and Chemotherapy.

[4]  Samuel A. Lee,et al.  Antifungal Lock Therapy , 2012, Antimicrobial Agents and Chemotherapy.

[5]  J. Pemán,et al.  Voriconazole inhibits biofilm formation in different species of the genus Candida. , 2012, The Journal of antimicrobial chemotherapy.

[6]  D. Lebeaux,et al.  Full and Broad-Spectrum In Vivo Eradication of Catheter-Associated Biofilms Using Gentamicin-EDTA Antibiotic Lock Therapy , 2012, Antimicrobial Agents and Chemotherapy.

[7]  J. Gaillat,et al.  Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections. , 2012, Medecine et maladies infectieuses.

[8]  R. Sentandreu,et al.  Pga13 in Candida albicans is localized in the cell wall and influences cell surface properties, morphogenesis and virulence. , 2012, Fungal genetics and biology : FG & B.

[9]  R. Darouiche,et al.  Role of Antibiofilm-Antimicrobial Agents in Controlling Device-Related Infections , 2011, The International journal of artificial organs.

[10]  S. Hernáez,et al.  Effect of Amphotericin B Alone or in Combination with Rifampicin or Clarithromycin Against Candida Species Biofilms , 2011, The International journal of artificial organs.

[11]  K. Ko,et al.  In vitro Evaluation of Antibiotic Lock Technique for the Treatment of Candida albicans, C. glabrata, and C. tropicalis Biofilms , 2010, Journal of Korean medical science.

[12]  Robin Patel,et al.  Clinical practice. Infection associated with prosthetic joints. , 2009, The New England journal of medicine.

[13]  J. Versalovic,et al.  Novel synergistic antibiofilm combinations for salvage of infected catheters. , 2009, Journal of medical microbiology.

[14]  D. Kontoyiannis,et al.  Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against Candida embedded in biofilm. , 2008, International journal of antimicrobial agents.

[15]  J. Pemán,et al.  Actividad de la anidulafungina sobre biopelículas de Candida , 2008 .

[16]  M. Fleischhacker,et al.  Secretion of E,E-Farnesol and Biofilm Formation in Eight Different Candida Species , 2008, Antimicrobial Agents and Chemotherapy.

[17]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[18]  J. Pemán,et al.  [Activity of anidulafungin against Candida biofilms]. , 2008, Revista iberoamericana de micologia.

[19]  J. Lopez-Ribot,et al.  A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing , 2008, Nature Protocols.

[20]  J. Pemán,et al.  Actividad in vitro de la anfotericina B y la anidulafungina sobre biopelículas de Candida albicans y Candida tropicalis , 2007 .

[21]  B. Wickes,et al.  Inhibition on Candida albicans biofilm formation using divalent cation chelators (EDTA) , 2007, Mycopathologia.

[22]  P. Lee,et al.  Antibiotic-lock therapy and erythromycin for treatment of catheter-related Candida parapsilosis and Staphylococcus aureus infections. , 2007, The Journal of antimicrobial chemotherapy.

[23]  M. El-Azizi.  Enhancement of the in vitro activity of amphotericin B against the biofilms of non-albicans Candida spp. by rifampicin and doxycycline. , 2007, Journal of medical microbiology.

[24]  B. Trautner,et al.  Combination of Tigecycline and N-Acetylcysteine Reduces Biofilm-Embedded Bacteria on Vascular Catheters , 2007, Antimicrobial Agents and Chemotherapy.

[25]  J. Pemán,et al.  [In vitro activity of amphotericin B and anidulafungin against Candida spp. biofilms]. , 2007, Revista iberoamericana de micologia.

[26]  I. Raad,et al.  Optimal Antimicrobial Catheter Lock Solution, Using Different Combinations of Minocycline, EDTA, and 25-Percent Ethanol, Rapidly Eradicates Organisms Embedded in Biofilm , 2006, Antimicrobial Agents and Chemotherapy.

[27]  P. Martín-Dávila,et al.  Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy. , 2006, The Journal of antimicrobial chemotherapy.

[28]  Andreas F Widmer,et al.  Infections associated with orthopedic implants , 2006, Current opinion in infectious diseases.

[29]  K. Ko,et al.  In vitro evaluation of the antibiotic lock technique (ALT) for the treatment of catheter-related infections caused by staphylococci. , 2006, The Journal of antimicrobial chemotherapy.

[30]  R. Donlan,et al.  Tetrasodium EDTA as a Novel Central Venous Catheter Lock Solution Against Biofilm , 2005, Infection Control & Hospital Epidemiology.

[31]  M. Hamilton,et al.  Statistical assessment of a laboratory method for growing biofilms. , 2005, Microbiology.

[32]  K. Ying,et al.  cDNA Microarray Analysis of Differential Gene Expression in Candida albicans Biofilm Exposed to Farnesol , 2005, Antimicrobial Agents and Chemotherapy.

[33]  A. Marzo,et al.  Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients , 2005, European Journal of Clinical Pharmacology.

[34]  M. Casanova,et al.  Changes in the cell wall glycoprotein composition of Candida albicans associated to the inhibition of germ tube formation by EDTA , 1994, Archives of Microbiology.

[35]  H. Elwing,et al.  N-Acetyl-l-Cysteine Affects Growth, Extracellular Polysaccharide Production, and Bacterial Biofilm Formation on Solid Surfaces , 2003, Applied and Environmental Microbiology.

[36]  M. Ghannoum,et al.  Mechanism of Fluconazole Resistance in Candida albicans Biofilms: Phase-Specific Role of Efflux Pumps and Membrane Sterols , 2003, Infection and Immunity.

[37]  B. Wickes,et al.  Inhibition of Candida albicans Biofilm Formation by Farnesol, a Quorum-Sensing Molecule , 2002, Applied and Environmental Microbiology.

[38]  M. Klepser,et al.  Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. , 2002, The Journal of antimicrobial chemotherapy.

[39]  S. Stepanović,et al.  A modified microtiter-plate test for quantification of staphylococcal biofilm formation. , 2000, Journal of microbiological methods.

[40]  G. Reid,et al.  Microbial Biofilms: Their Development and Significance for Medical Device—Related Infections , 1999, Journal of clinical pharmacology.

[41]  P. Tulkens,et al.  Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation , 1996, FEBS letters.